Business ❯Finance ❯Stock Market ❯Pharmaceutical Stocks

Novo Nordisk

Novo Nordisk Faces Setbacks as CagriSema Trial Results Disappoint Investors

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Novo Nordisk Shares Plunge After Weight-Loss Drug Trial Falls Short

Eli Lilly's Q2 Earnings Surge on High Demand for Weight-Loss Drugs